One-year real-world benefits of Tandem Control-IQ technology on glucose management and person-reported outcomes in adults with type 1 diabetes: a prospective observational cohort study
Diabetologia · 2025
DOI: 10.1007/s00125-025-06366-x ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Diabetologia, 2025. Verfasst von Jolien De Meulemeester und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, University Hospitals Leuven - KU Leuven, Leuven, Belgium. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Blood Glucose, Glycemic Control, Hypoglycemic Agents. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Tandem Diabetes Care, Dexcom.
Themen: Diabetes mellitus
Abstract (Originalsprache)
AIMS/HYPOTHESIS: This multicentre prospective observational cohort study aimed to evaluate real-world changes in glycaemic and person-reported outcomes after 1 year's use of Control-IQ technology in adults with type 1 diabetes. METHODS: Adults who started with Control-IQ between December 2021 and December 2022 were consecutively recruited in 13 Belgian diabetes centres. Data were collected at start and after 4, 8 and 12 months. The primary endpoint was the evolution of time in range (TIR; glucose levels of 3.9-10.0 mmol/l). Data are reported as mean ± SD or least-squares mean (95% CI). RESULTS: A total of 473 adults were included, with a mean age of 38.5 ± 13.1 years and of whom 57.3% were female. TIR increased from 58.8% (95% CI 56.7, 60.9) at start to 70.9% (69.1, 72.8) at 12 months (p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, University Hospitals Leuven - KU Leuven, Leuven, Belgium.
- Department of Diabetology and Endocrinology, University Hospital Brussels - Vrije Universiteit Brussel, Jette, Belgium.
- Department of Endocrinology, Diabetology & Metabolism, University Hospital Antwerp - University of Antwerp, Edegem, Belgium.
- Department of Endocrinology, Onze-Lieve-Vrouw Hospital Aalst, Aalst, Belgium.
- Department of Endocrinology, AZ Sint-Jan Brugge, Brugge, Belgium.
- Department of Endocrinology, Vitaz, Sint-Niklaas, Belgium.
Förderung
- Tandem Diabetes Care
- Dexcom
Zitieren
APA
De Meulemeester, J., Keymeulen, B., De Block, C., Van Huffel, L., Taes, Y., Ballaux, D., Spincemaille, K., Lapauw, B., Vanhaverbeke, G., Lowyck, I., Vercammen, C., Colin, I. M., Preumont, V., Charleer, S., Fieuws, S., Mathieu, C., & Gillard, P. (2025). One-year real-world benefits of Tandem Control-IQ technology on glucose management and person-reported outcomes in adults with type 1 diabetes: a prospective observational cohort study. Diabetologia. https://doi.org/10.1007/s00125-025-06366-x
Vancouver
De Meulemeester J, Keymeulen B, De Block C, Van Huffel L, Taes Y, Ballaux D, et al. One-year real-world benefits of Tandem Control-IQ technology on glucose management and person-reported outcomes in adults with type 1 diabetes: a prospective observational cohort study. Diabetologia. 2025. doi:10.1007/s00125-025-06366-x
BibTeX
@article{DeMeulemeester2025,
author = {De Meulemeester, Jolien and Keymeulen, Bart and De Block, Christophe and Van Huffel, Liesbeth and Taes, Youri and Ballaux, Dominique and Spincemaille, Katrien and Lapauw, Bruno and Vanhaverbeke, Gerd and Lowyck, Ine and Vercammen, Chris and Colin, Ides M and Preumont, Vanessa and Charleer, Sara and Fieuws, Steffen and Mathieu, Chantal and Gillard, Pieter},
title = {One-year real-world benefits of Tandem Control-IQ technology on glucose management and person-reported outcomes in adults with type 1 diabetes: a prospective observational cohort study},
journal = {Diabetologia},
year = {2025},
doi = {10.1007/s00125-025-06366-x}
}
EUVIMED